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Abstract
Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. 
Typically, MDR bacteria are associated with nosocomial infections. However, some MDR bacteria 
have become quite prevalent causes of community-acquired infections. The spread of MDR 
bacteria into the community is a crucial development, and is associated with increased morbidity, 
mortality, healthcare costs and antibiotic use. Factors associated with community dissemination of 
MDR bacteria overlap but are distinct from those associated with nosocomial spread. Community-
associated (CA) MDR bacteria have an antibiotic resistance phenotype that is stable in the absence 
of antibiotic pressure of the type normally observed in hospitals or nursing homes. An exception to 
this rule may be those CA-MDR bacteria, of which the prevalence is driven by the presence of 
antibiotics in the food chain. Additionally, the colonization of otherwise healthy hosts is a 
common characteristic of CA-MDR bacteria. However, subtle immune deficiencies may still be 
present in the subjects colonized with specific CA-MDR bacteria. Methicillin-resistant S. aureus 
(MRSA) is the most prevalent of CA-MDR bacteria. CA-MRSA also has the greatest impact on 
morbidity and mortality. The main threat on the horizon is represented by Enterobacteriaceae. The 
production of extended spectrum β-lactamases in Enterobacteriaceae encountered in the 
community is becoming increasingly prevalent. Of great concern is the potential for the 
acquisition of carbapenemase genes in CA-Enterobacteriaceae. Prevention of further community 
spread of MDR bacteria is of the utmost importance, and will require a multi-disciplinary 
approach involving all stakeholders.
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Introduction
Multidrug resistant (MDR) bacteria are well-recognized to be one of the most important 
current public health problems. The Infectious Diseases Society of America (IDSA) 
recognizes antimicrobial resistance as “one of the greatest threats to human health 
worldwide”1. Several issues underlie the critical danger that is posed by the rise of MDR 
bacteria. First and most importantly, outcomes in patients infected with MDR bacteria tend 
to be worse as compared to patients infected with more susceptible organisms2, 3. In this 
way, rising rates of antibacterial resistance have an impact on all aspects of modern 
medicine, and threaten to decrease the yield of many accomplishments such as cancer care, 
transplantation and surgical procedures4. Second, tremendous added costs are associated 
with these infections. In the US, associated annual additional costs of infections caused by 
resistant organisms as compared to susceptible organisms are estimated between $21 billion 
and $34 billion1. Third, the prevalence of specific MDR bacteria is closely linked to the use 
of broad spectrum antibiotics, both for empiric as well as for definitive therapy5. This 
increased use in turn leads to even higher rates of MDR bacteria, thus creating a vicious 
cycle.
Typically, MDR bacteria are associated with nosocomial infections. However, some MDR 
bacteria have become quite prevalent causes of community-acquired infections. This is an 
important development as community spread of MDR bacteria leads to a large increase of 
the population-at-risk, and subsequently an increase in the number of infections caused by 
MDR bacteria. In addition, when the incidence of a certain resistance pattern in bacteria 
causing community-acquired infections exceeds a specific threshold, broader spectrum 
antibacterials and/or combination antibacterial therapy are indicated for the empiric 
treatment of community-acquired infections. In this review, we will outline the trends in and 
epidemiology of community prevalence of various MDR bacteria.
Community-associated, health-care associated and nosocomial infections
Infections can be divided into community onset and nosocomial acquisition. The widely 
used cut-off to distinguish between these two categories is whether the onset of infection 
was within the first 48 hours of hospitalization (community-onset) or later (nosocomial). 
Limitations of this division include the arbitrary nature of the 48 hour time point, as well as 
the dependence on the timing of diagnosis. If cultures are performed earlier during 
hospitalization, more infections are likely to be labeled as community-onset.
The category of community-onset can then be further subdivided into community-acquired 
and healthcare-associated, based on work pioneered by Morin et al. and Friedman et al.6, 7. 
Generally, an infection is deemed to be healthcare-associated if a patient was hospitalized in 
an acute care hospital for two or more days within 90 days of the infection; resided in a 
nursing home or long-term care facility; received recent intravenous antibiotic therapy, 
chemotherapy, or wound care within the past 30 days of the current infection; or attended a 
hospital or hemodialysis clinic8.
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The remaining category includes those patients who have a community-onset infection, and 
who do not meet any of the above criteria for health-care associated infection. These 
infections are considered to be community-acquired. However, for the purposes of 
evaluating MDR bacteria in the community, these definitions may not tell the whole story. 
Patients tend to get infected with organisms with which they were previously colonized. 
Therefore, it is the timing of colonization, rather than the timing of diagnosis of infection 
that is crucially important to determine the origin of the MDR bacteria. Studies that have 
employed screening of non-infected individuals have addressed these questions for some 
MDR bacteria in certain populations.
Requirements for Transition from Nosocomial Pathogen to Community-
Associated Pathogen
The commonality of risk factors of MDR organisms, as well as opportunistic organisms such 
Clostridium difficile and Candida species was described by Safdar and Maki9. Many studies 
have studied specific risk factors for MDR bacteria and for the most part have found 
overlapping sets of risk factors. Exposure to antibiotics is a risk factor which is almost 
always found in studies with sufficient power to evaluate this risk. The specific antibiotic 
class associated with the risk for developing a specific antimicrobial resistance pattern may 
vary. Often, a simple association between the use of a specific antibacterial and resistance to 
that antibiotic is described. For instance, tigecycline use in patients with carbapenem-
resistant Klebsiella pneumoniae was found to subsequently lead to tigecycline resistance in 
the same bacteria of those same patients10. Specific types of epidemiologic studies (case-
case-control studies) often needed to determine the true extent of the risk of use of an 
antibiotic contributing to resistance to itself11, 12. Sometimes, patterns are more complicated. 
As an example, the use of ceftriaxone use – but not other cephalosporin use – was associated 
with the incidence of bloodstream infections caused by vancomycin-resistant Enterococci 
(VRE)13. These examples are clear indications of the importance of antimicrobial 
stewardship at all levels – in hospitalized patients, in patients treated in the community, as 
well as non-medical antibiotic use – for the control of antimicrobial resistance.
Healthcare exposure is an additional key risk factor for MDR bacteria. The presence of 
indwelling medical devices such as urinary catheters, feeding tubes, endotracheal tubes, and 
vascular lines is also a commonly identified risk factor9. Other categories of risk factors for 
infection with or colonization by MDR bacteria includes immunosuppressed states such as 
solid organ or hematopoietic stem cell transplant recipients, as well as other comorbid 
conditions such as renal failure. The impact of these last two categories is often difficult to 
definitively establish as there is usually considerable overlap with the first three categories.
In order for MDR bacteria to become widespread in the community, these traditional risk 
factors and their implied role in the pathophysiology of colonization have to become of 
lesser importance. First, the MDR phenotype has to be stable in the absence of antibiotic 
pressure of the type normally observed in hospitals or nursing homes. The potential 
implications of this requirement include an ability to compete with wild-type, antibiotic-
susceptible bacteria, as well as a genetic stability of genes conferring the antibiotic 
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resistance phenotype of interest. This means that resistance genes that are associated with a 
fitness cost to the organism are unlikely to become widespread in the community, unless 
compensatory genetic content is accumulated as well, or if resistance gene expression is 
fully inducible upon antibiotic exposure. Examples of such inducible genes are the 
erythromycin resistance methylase (erm) genes, which are found in mycobacteria and 
Staphylococcus aureus. The products of these genes are only made if the bacteria are 
exposed to specific antibiotic classes, leading to rapid phenotypic resistance to those 
antibiotics.
Furthermore, MDR bacteria that are successful in the community have to be able to persist 
without having to form biofilms on non-organic matter. This involves competition with other 
microbial flora in specific microbiome settings such as the skin, nares, mouth and gut. Of 
course, even in the absence of foreign material, biofilm formation remains an important 
component of bacterial persistence. Biofilm formation is an essential pathophysiologic 
component of periodontal infections, gastric infection with Helicobacter pylori, middle ear 
infection, urinary cystitis, and many other common infections14. MDR bacteria with the 
ability to form biofilms in the absence of foreign material will be more likely to become 
common in community settings.
In addition, community-associated MDR bacteria have to be able to coexist with the immune 
systems of otherwise healthy human hosts in the absence of obvious immunosuppression. 
Nonetheless, specific polymorphisms in immunity genes of the host may facilitate 
colonization of select bacteria. In persistent S. aureus nasal carriage, human host genetics 
were even postulated to be the predominant determinant15.
In summary, it is clear that genetic content encoding for several distinct functions needs to 
be accumulated for a specific strain of MDR bacteria to become community-associated.
MRSA
Methicillin-resistant S. aureus (MRSA) is probably the best example of a prevalent and 
important MDR bacterium that has successfully transitioned from an almost exclusively 
nosocomial setting to being widespread in the community. The epidemiology of community-
associated MRSA (CA-MRSA) has been extensively reviewed elsewhere16, 17. Here, we will 
give a brief overview of MRSA in the community as it may be predictive of the behavior of 
other MDR bacteria.
As early as 1982 an outbreak of CA-MRSA was reported in Detroit18. In this outbreak, more 
than half of patients were intravenous drug users, and the remaining patients had several 
comorbidities that put them at risk. Importantly, various different strains were found in this 
outbreak18. It was not until the early 1990’s that more genuine CA-MRSA outbreaks began 
to be reported. These outbreaks occurred in populations without specific risk factors. The 
MRSA strains involved were generally monoclonal or oligoclonal and rather than being 
extensively multidrug resistant such as nosocomial MRSA strains at that time, these CA-
MRSA strains were susceptible to many non-β-lactam antibiotics. In the early 2000’s, a new 
strain of CA-MRSA – USA300 – became the predominant CA-MRSA in the United States, 
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effectively replacing the previous USA400 CA-MRSA strain16. This USA300 strain is 
characterized by the presence of the staphylococcal cassette chromosome mec (SCCmec) 
type IV as well as of genes encoding for Panton-Valentine leucocidin (PVL) toxins19. 
Households are an important reservoir for the USA300 strain. In a recent study that utilized 
whole genome sequencing data, USA300 MRSA was shown to persist in households 
between 2 and 8 years prior to admission of a symptomatic patient from that household, and 
to continue to persist for at least another year after that20. This and other evidence shows 
conclusively that this specific strain of MRSA has been able to become entrenched in a 
community setting in the absence of ongoing antibiotic pressure. In addition, specific strains 
of CA-MRSA have been shown to be associated with exposure to lifestock; so-called 
lifestock-associated (LA) MRSA. The ST398 LA-MRSA is predominantly found in Europe 
and America, whereas ST9 LA-MRSA is encountered in Asia21.
Vancomycin-resistant Enterococci (VRE)
Vancomycin-resistant enterococci (VRE) emerged in the late 1980’s, and became a common 
cause of nosocomial infections in the 1990’s22. Studies in the 1990’s did not detect the 
presence of vancomycin resistance in enterococci isolated from subjects without healthcare 
exposure in the United States23, 24. In contrast, in European studies from the same time 
period, VRE was detected in the stool of healthy volunteers25. In addition, VRE was 
commonly found in European food animals26, 27. The underlying reason for this difference 
between Europe and the United States is the use of avoparcin – a glycopeptide antibiotic – 
for the purpose of promoting growth in food animals. Avoparcin was never approved for use 
in the United States or Canada, but its use was widespread in Europe up to 199727. After a 
ban on avoparcin in animal husbandry, rates of VRE in both animal samples, as well as in 
samples from human volunteers started to decrease25, 27. These important data illustrate the 
critical link between antibiotic use in the food industry and antimicrobial resistance rates in 
humans. It also indicates that it is never too late to make a change and that banning 
antimicrobials from our food chain may have an almost instantaneous positive – and cost-
saving – effect.
Around 2000, community-associated VRE began to appear in the US. In a screening study 
of patients attending an ambulatory care clinic in Nashville, Tennessee, 3 patients tested 
positive for VRE out of 100 patients screened. One of these patients came in for her annual 
check-up and had no prior healthcare exposures28. Also, VRE was found in wastewater from 
a semi-closed agri-food system29. Nonetheless, VRE remains an uncommon pathogen in 
community-associated infections. In 289 patients with community-onset VRE, 85% of 
patients had been hospitalized, and 71% had antimicrobial exposure in the last 3 months, 
respectively30. In another study that included 81 patients with community-onset VRE 
bacteremia, 79% of patients had prior hospitalizations31. These data indicate that even in 
those patients where VRE is detected on admission or early during hospitalization, 
acquisition likely occurred in the healthcare setting. This acquisition was driven by 
traditional risk factors of antimicrobial exposure, healthcare exposure, chronic illness, 
indwelling devices, malignancies and immunosuppression30, 31.
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The discrepancy between the community spread of MRSA and VRE is notable, as both S. 
aureus and enterococci are common human colonizers. However, overall colonization with 
enterococci is much more universal than with S. aureus, and S. aureus is not truly a 
commensal. Apparently – in contrast to MRSA – high prevalence of current strains of VRE 
in the community requires either an ongoing incoming supply of VRE into the shared 
community gut microbiome through the food chain, or a high level of antibiotic pressure. 
Fitness cost of maintaining a vancomycin resistant phenotype would be an intuitive 
explanation for the relative lack of true community-associated VRE infections. However, the 
fitness cost of vancomycin resistance appears to be minimal for enterococci, especially in 
the context of inducible resistance32, 33. A recent study suggests that pheromone-mediated 
killing of VRE may account for why vancomycin-susceptible commensal enterococci 
outcompete VRE in the human gut34. In this study, the prototype multidrug-resistant clinical 
isolate strain E. faecalis V583 was killed by human fecal flora, whereas commensal 
antibiotic-susceptible E. faecalis was able to survive in the presence of flora. The killing 
effect was traced to pheromone production by commensal E. faecalis strains34.
Carbapenem-resistant Acinetobacter baumannii (CRAB)
Acinetobacter baumannii infections are commonly encountered in hospitalized patients, 
especially in the intensive care35. However, community-associated A. baumannii infections 
have been well-described especially in (sub-) tropical climates, including Asia and 
Australia36. These are generally associated with pharyngeal carriage and are linked to 
alcohol abuse and smoking36. These are serious infections and the attributable mortality in 
80 patients with bacteremia and/or pneumonia from various case series was reported at 
56%36. Community reservoirs for A. baumannii include environmental sources such as soil 
and vegetables, as well as human and animal skin and throat carriage. Furthermore, A. 
baumannii has also been recovered from human lice37.
A. baumannii is intrinsically resistant to several antibiotic classes. In addition, carbapenem 
resistance may occur through acquisition of carbapenemases such as IMP-like 
carbapenemases and/or oxacillinases (OXA)38. The rate of carbapenem resistance in clinical 
isolates of A. baumannii rose sharply from 9% to 40% between 1995 and 2004 in the US35. 
More recent studies suggest that this rate has remained around 40%39, 40. In contrast, the 
rate of carbapenem resistance in Acinetobacter infections isolated from community-dwelling 
patients has remained around 4%39. Similarly, resistance to carbapenems was detected in 
only one out of 23 community-dwelling volunteers who had A. baumannii isolated from 
their hands41. In an Australian study on 36 patients with community-onset bacteremic 
Acinetobacter pneumonia, all tested isolates were susceptible to carbapenems42. A more 
worrisome report from China described 32 patients with community-acquired pneumonia 
caused by A. baumannii. Three and 6 isolates were non-susceptible to meropenem and 
imipenem, respectively. In addition, blaOXA-23 found in 12 of 15 tested isolates, some of 
which tested susceptible to both meropenem and imipenem43. Of note, 87% of patients with 
MDR A. baumannii had a “hospitalization history”, suggesting that these did not truly 
represent community-associated infections43.
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In summary, community-associated CRAB appears to remain uncommon, likely reflecting 
the natural habitats of Acinetobacter species, and the differences between true community 
strains found to cause infections in Asia and Australia and hospital-associated strains. Of 
concern is the potential for acquisition of carbapenemases by such a community strain, 
especially in high antibiotic use areas in Asia.
Multi-drug resistant Pseudomonas aeruginosa
P. aeruginosa is a common cause of nosocomial infections, including bloodstream infections 
and pneumonia. It prefers moist environments and can be found in a large variety of places 
in the hospital, including sink traps and aerators, various equipment such as scopes and 
respiratory gear and contaminated solutions44. In addition, P. aeruginosa may be present on 
fresh fruits and vegetables as well as on the fingernails of healthcare providers44.
Similar to A. baumannii, P. aeruginosa is intrinsically resistant to many antibiotic classes. 
Furthermore, additional acquired antibiotic resistance arises relatively easily and quickly 
after antibiotic exposure. Some patients have chronic biofilm-mediated pseudomonal 
colonization; patients with cystic fibrosis (CF) are an important example45. In these patients, 
repeated antibiotic courses are the rule, as is the subsequent development of MDR strains. 
While these patients are often community-dwelling, these infections are clearly healthcare-
associated. Nonetheless, spread of MDR isolates between patients with CF has been well 
described and is an important infection control risk46.
True community-associated infections with MDR P. aeruginosa fortunately remain very 
uncommon47, 48. In a cohort of 60 patients with community-acquired bloodstream infections 
with P. aeruginosa, 100% of isolates were meropenem susceptible, and 95% were 
susceptible to piperacillin/tazobactam and ceftazidime49. A case report from Turkey 
describes a young man without healthcare exposure who presented with a pyogenic liver 
abscess caused by a P. aeruginosa strain that was only susceptible to imipenem, amikacin, 
and colistin 50.
Enterobacteriaceae that produce extended spectrum β-lactamases
Enterobacteriaceae are very common causes of community-associated infections, including 
urinary tract infections and bacteremia. Unfortunately – in contrast to the situation described 
above with P. aeruginosa and A. baumannii – there is widespread resistance in community-
associated enterobacteriaceae isolates mediated by extended spectrum β-lactamases 
(ESBL) 51. This is a global phenomenon and involves patients of all ages including pediatric 
populations. In a multicenter, prospective US study over a one year period in 2009–2010, 
4% of E. coli community-onset isolates were ESBL producers52. The majority reflected 
urinary tract infections such as cystitis or pyelonephritis. The most common ESBL 
encountered were of the CTX-M group (91%), the remaining ESBLs were either SHV (8%) 
or CMY-2 (1%). Most isolates (54%) belonged to the ST131 clonal group52. E. coli ST131 
is a globally disseminated MDR clone, and is characterized by resistance to 
fluoroquinolones in addition to production of CTX-M type ESBL53.
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In Asia, the Middle East, South America and some parts of Europe, community-onset 
infection with ESBL-producing E. coli is extraordinarily frequent. Lower prevalence regions 
include North America, some parts of Northern Europe, Australia and New Zealand. 
Specific risk factors for community-onset ESBL-producing E. coli infections have been 
found in these low prevalence regions. Reported risk factors from a Chicago-based study for 
ESBL-producing E. coli included travel to India (OR 14.4), increasing age (OR 1.04 per 
year), and prior use of ciprofloxacin (OR 3.92)54. In a German survey-based study, risk 
factors for ESBL-positive E.coli colonization included an Asian language being the primary 
language spoken in the household (OR 13.4) and frequent pork consumption (OR 3.5)55. A 
population-based study in London also suggested South-Asian ethnicity and older age as 
risk factors for ESBL-positive E. coli bacteriuria56. A study performed in Australia and New 
Zealand also found that birth on the Indian subcontinent or travel to SouthEast Asia, China, 
India, Africa or the Middle East were risk factors for community-onset third generation 
cephalosporin resistant E. coli infections57.
A significant problem in Asia is disseminated infection with hypervirulent Klebsiella 
pneumoniae strains. These “hypermucoviscous” strains have a propensity to cause 
community-onset pyogenic liver abscess and sometimes metastatic infections, including 
meningitis58. While these strains were typically susceptible to multiple antibiotics, 
community-onset ESBL-producing strains are now well described and appear to be 
increasing59.
Community-associated ESBL-producing enterobacteriaceae are of specific concern as 
treatment requires broad-spectrum antibiotics. Whether carbapenems are always indicated 
for severe infections caused by ESBL-producing organisms remains controversial. 
Retrospective studies suggest that carbapenem treatment is either superior or equivalent to 
treatment with alternatives such as piperacillin/tazobactam60, 61. Nevertheless, most 
clinicians consider a carbapenem the drug of choice for serious infections caused by ESBL-
producing enterobacteriaceae. Therefore, widespread infections from the community with 
these organisms is likely to lead to a dramatic increase in empiric carbapenem use. A 
randomized controlled trial is ongoing to address the question of comparative efficacy of 
piperacillin-tazobactam vs. meropenem to treat bloodstream infections caused by 
ceftriaxone non-susceptible E. coli and Klebsiella sp., and has enrolled more than 100 
patients at the time of writing (MERINO trial, NCT02176122).
Carbapenemase-producing Enterobacteriaceae
Carbapenem-resistant enterobacteriaceae (CRE) represent an immediate public health threat 
that requires urgent and aggressive action1, 62. CRE are resistant to most antibiotics and 
clinical outcomes after CRE infections are generally poor63–68. While less frequent than 
carbapenem-resistant Klebsiella pneumoniae (CRKP), carbapenem resistant E. coli (CREC) 
constitute an important subset of CRE, and are on the rise globally and outbreaks have been 
reported in the US69, 70. To date, most CRE infections in the United States and Europe are 
health-care associated, with patients from long term care facilities at especially high risk71. 
Although data from Asia are somewhat sparse, carbapenemases have been found in bacteria 
recovered from drinking water in India and in food-producing animals in China72, 73. This 
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raises the spectre of huge numbers of people in these large countries being colonized with 
CRE. Clinical reports of the consequences of this are awaited.
Given the rapid global spread of ESBL-producing E. coli ST131, the obvious concern is for 
this highly successful clone to acquire a carbapenemase. Indeed, several reports of 
carbapenemase-producing E. coli ST131 have been published74–76. In a study from India, 
ST131 clinical isolates were compared to non-ST131 clinical isolates. Overall 20% of 
clinical isolates were positive for metallo-β-lactamases such as blaNDM-1, which was evenly 
distributed between ST131 and non-ST131 E. coli75. As the epidemiology of ESBL is 
estimated to be about 10 years ahead of that of the carbapenemases, it is likely that 
community-associated carbapenem-resistant ST131 E. coli will become a major threat in the 
near future.
Prevention
Prevention of further spread of MDR bacteria in the community is one of the most urgent 
public health challenges. Unfortunately, national or even regional data on antibiotic 
susceptibilities are often limited. In addition, when these data are available in some form, the 
accompanying epidemiologic metadata is usually too restricted to determine which isolates 
are truly community-associated. Furthermore, clinical infections are generally the tip of the 
proverbial iceberg and once a signal is generated that is sufficient in amplitude to get the 
attention of policy-makers, subclinical spread has already occurred.
Any successful prevention strategy will have to consist of a multi-pronged approach and 
involve all stakeholders. In addition to human clinical antimicrobial stewardship, we need to 
remove antibiotics from the food chain. Furthermore, we need to limit the amount of 
xenobiotics such as quaternary ammonium compounds that reach the environment77. 
Another challenging step in limiting exposure of bacteria to antibiotics is the treatment of 
contaminated wastewater such as that generated by pharmaceutical factories and medical 
facilities. For instance, a study evaluated samples collected from a wastewater treatment 
plant in India that received water from 90 regional bulk drug manufacturers containing – 
amongst other compounds – higher concentrations of ciprofloxacin than are generally found 
in the blood of patients who are being treated with this agent. Bacteria recovered from this 
water were tested against 39 antibiotics. Approximately 30% of bacteria were resistant 29–
32 antibiotics tested, and another ~20% were resistant to 33–36 antibiotics78. The magnitude 
of this effect, combined with the knowledge that soil-dwelling bacteria will pass on 
resistance genes to more clinically relevant bacteria, illustrates the importance of limiting 
this contamination79.
Antimicrobial stewardship is developing rapidly as a hospital specialty. Stewardship teams 
often will combine strengths from Infectious Disease medical specialist and doctors of 
pharmacy to evaluate the appropriateness of choice and duration of antibiotic strategies80. 
However, most antibiotics are prescribed in ambulatory care and more attention is needed in 
this realm to really impact overall community antibiotic exposure81. This will not only 
require a paradigm shift in the behavior of prescribers, but also a cultural shift in the public 
on the risks and benefits of antibiotics. Rapid diagnostic testing to identify MDR bacteria 
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more quickly and thus limit the empiric use of unnecessarily broad antibiotics will be of 
great significance. Also, rapid testing to diagnose alternative, non-bacterial etiologies is 
important.
An important question is whether any interventions can address the issue of chronic 
colonization with MDR bacteria. Obviously, decolonizing these patients would decrease the 
risk of transmission. Also, the burden on the individual patient of this condition should not 
be underestimated. In many healthcare systems, patients with MRSA or CRE are “labeled” 
as carriers for life, resulting in the institution of isolation precautions whenever they are 
admitted to the hospital. This has multiple adverse effects and leads to decreased patient 
satisfaction82. For these reasons, decolonization is a theoretically attractive option. However, 
most decolonizing strategies involve the use of antibiotics. For MRSA decolonization, most 
strategies involve some combination of intranasal mupirocin with topical chlorhexidine83. 
This approach has been shown to be effective in decreasing infections after surgery84. 
However, the effect is generally short-lived and recurrence of colonization is the rule. For 
enteric bacteria, no good options are currently available. Various selective gut 
decontamination strategies have been described, but none have shown true promise. In 
addition, with growing knowledge of the role of the gut microbiome in the defense against 
MDR bacteria, it would seem counter-intuitive to give even more antibiotics. Modulating the 
gut microbiome either through probiotics or through fecal microbiota transplantation is a 
promising, but as of yet experimental method of decolonizing patients.
Summary
In conclusion, wide variability is observed in community spread of common nosocomial 
MDR pathogens. This variability is likely secondary to a number of factors that include the 
natural habitats of the bacteria, and the competition present in those niches. In addition, 
certain strains of bacteria appear to be much more able to maintain their MDR phenotype 
and spread throughout the community. This is most likely secondary to additional genetic 
content that compensates for the relative fitness cost of the expression of genes associated 
with antibacterial resistance. Community spread of MDR bacteria is an important public 
health threat that should be approached urgently and pro-actively.
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• Wide variability is observed in community spread of common nosocomial 
MDR pathogens.
• This variability is likely secondary to a number of factors that include the 
natural habitats of the bacteria, and the competition present in those niches.
• In addition, certain strains of bacteria appear to be much more able to 
maintain their MDR phenotype and spread throughout the community.
• This is most likely secondary to additional genetic content that compensates 
for the relative fitness cost of the expression of genes associated with 
antibacterial resistance.
• Community spread of MDR bacteria is an important public health threat that 
should be approached urgently and pro-actively.
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Table 1
Multidrug resistant bacteria observed in the community.
MDR Phenotype Epidemiologic setting of community-onset infections
MRSA Household colonization; farm animal exposure (emerging)
VRE Typically healthcare-associated
ESBL + E. coli Endemic in Asia; in low-prevalence areas travel to Asia
CRE Rare at present; emerging in India and China
CR-PA Extremely rare
CR-AB Extremely rare
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